Geneva, Oct. 21 -- International Clinical Trials Registry received information related to the study (NCT07198074) titled 'Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer' on Sept. 27.
Study Type: Interventional
Study Design:
Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).
Primary Sponsor: National Cancer Institute (NCI)
Condition:
Advanced Endometrial Carcinoma
Recurrent Endometrial Carcinoma
Intervention:
Biological: Bevacizumab
Procedure: Biospecimen Collection
Drug: Carboplatin
Procedure: Computed Tomography
Proced...